Genmab A/S GMAB Stock Forecast
AI-powered price prediction and analysis for Genmab A/S · Total · absolute moveSwitch to Alpha
See GMAB's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Genmab A/S
Genmab A/S (GMAB) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where GMAB sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| GMAB Genmab A/S | ▶ | $23.73B | 1.5x |
| LLY Eli Lilly & Co | ▼ | $1.14T | 40.6x |
| JNJ Johnson & Johnson | ▼ | $611.90B | 29.5x |
| ABBV Abbvie Inc. | ▼ | $500.94B | 73.3x |
| MRK Merck & Co., Inc. | ▼ | $363.59B | 117.9x |
| NVS Novartis Ag | ▼ | $280.27B | 8.8x |
| AZN Astrazeneca Plc | ▼ | $251.15B | 11.7x |
| ABT Abbott Laboratories | ▼ | $179.05B | 28.8x |
| NVO Novo Nordisk A S | ▼ | $169.41B | 2.8x |
| PFE Pfizer Inc | ▼ | $166.49B | 36.1x |
| VRTX Vertex Pharmaceuticals Inc / … | ▼ | $126.35B | 28.7x |
| BMY Bristol Myers Squibb Co | ▼ | $121.09B | 13.0x |
| SNY Sanofi | ▼ | $98.05B | – |
| GSK Gsk Plc | ▼ | $96.58B | 5.3x |
| REGN Regeneron Pharmaceuticals, Inc. | ▼ | $80.48B | 19.3x |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.45B | 67.1x |
| ONC Beone Medicines Ltd. | ▲ | $39.96B | 1212.0x |
| RPRX Royalty Pharma Plc | ▶ | $33.92B | 41.6x |
| ZTS Zoetis Inc. | ▼ | $31.11B | 11.9x |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $30.24B | – |
| ALNY Alnylam Pharmaceuticals, Inc. | ▶ | $30.04B | 56.4x |
| ATHE Alterity Therapeutics Ltd | ▶ | $25.65B | – |
| ZLAB Zai Lab Ltd | ▶ | $25.26B | – |
| ROIV Roivant Sciences Ltd. | ▲ | $24.28B | – |
| UTHR United Therapeutics Corp | ▼ | $23.16B | 17.7x |
| INSM Insmed Inc | ▶ | $21.36B | – |
| VTRS Viatris Inc | ▶ | $20.03B | – |
| ASND Ascendis Pharma A/S | ▲ | $14.97B | – |
| JAZZ Jazz Pharmaceuticals Plc | ▼ | $13.61B | 14.3x |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.69B | – |
| CORT Corcept Therapeutics Inc | ▲ | $12.56B | 130.6x |
| SMMT Summit Therapeutics Inc. | ▲ | $12.07B | – |
| ELAN Elanco Animal Health Inc | ▶ | $11.27B | – |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.67B | 68.9x |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.64B | 14.0x |
| MDGL Madrigal Pharmaceuticals, Inc. | ▼ | $10.63B | – |
| PTGX Protagonist Therapeutics, Inc | ▶ | $8.82B | 172.5x |
| CYTK Cytokinetics Inc | ▲ | $8.82B | – |
| AXSM Axsome Therapeutics, Inc. | ▲ | $8.50B | – |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.25B | – |
| ABVX Abivax S.A. | ▼ | $7.68B | – |
| IONS Ionis Pharmaceuticals Inc | ▲ | $7.10B | – |
| SYRE Spyre Therapeutics, Inc. | ▲ | $6.93B | – |
| PRAX Praxis Precision Medicines, Inc. | ▲ | $6.67B | – |
| ALKS Alkermes Plc. | ▲ | $6.56B | 43.0x |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▼ | $6.16B | 86.6x |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.04B | 57.3x |
| BLTE Belite Bio, Inc | ▲ | $6.01B | – |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.97B | – |
| LGND Ligand Pharmaceuticals Inc | ▼ | $5.88B | 28.6x |
| BLRX Biolinerx Ltd. | ▶ | $5.43B | – |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.19B | – |
| ERAS Erasca, Inc. | ▲ | $5.14B | – |
| ORKA Oruka Therapeutics, Inc. | ▲ | $5.08B | – |
| TVTX Travere Therapeutics, Inc. | ▲ | $5.02B | – |
| PTCT Ptc Therapeutics, Inc. | ▲ | $4.98B | – |
| COGT Cogent Biosciences, Inc. | ▲ | $4.88B | – |
| MANE Veradermics, Inc | ▲ | $4.74B | – |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.18B | – |
| INDV Indivior Pharmaceuticals, Inc. | ▼ | $4.03B | 13.8x |
FAQ
Is Genmab A/S a good stock to buy?
Our AI analyzes Genmab A/S daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Genmab A/S predictions?
For GMAB, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 2.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 8.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Genmab A/S forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Genmab A/S? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.